Update on Mast Cell Proteases as Drug Targets

Area of Science:

• Biochemistry
• Pharmacology
• Immunology

Background:

• Mast cells release proteases from granules upon degranulation.
• These proteases are implicated in various diseases, including asthma, ulcerative colitis, and bronchiectasis.
• Specific proteases like β-tryptases, chymases, and dipeptidyl peptidase-I are key targets for therapeutic intervention.

Purpose of the Study:

• To evaluate the therapeutic potential of mast cell protease inhibitors.
• To assess the clinical efficacy and safety of inhibitors targeting β-tryptases, chymases, and dipeptidyl peptidase-I.

Main Methods:

• Preclinical studies of small-molecule and antibody-based inhibitors.
• Early-phase and Phase II human clinical trials for different protease inhibitors.
• Assessment of therapeutic benefits and safety profiles in human subjects.

Main Results:

• β-tryptase inhibitors demonstrated preclinical promise and showed some benefit in early human trials.
• Chymase inhibitors were safely administered in Phase II trials but did not show significant benefits.
• Dipeptidyl peptidase-I inhibitors improved bronchiectasis, likely by inactivating the enzyme in neutrophils.

Conclusions:

• Mast cell protease inhibitors represent a promising therapeutic strategy for various inflammatory and fibrotic diseases.
• Clinical outcomes vary among different protease inhibitors, highlighting the need for target-specific approaches.
• Further research is warranted to optimize the development and application of these inhibitors for specific conditions.